WCLC 2022 | JIN-A02: a highly effective 4th generation EGFR-TKI, targeting EGFR C797S triple mutation in NSCLC

EGFR mutations are the most commonly occurring mutation in non-small cell lung cancer (NSCLC) and occur in approximately 50% of Asian NSCLC. EGFR-targeted therapeutics have revolutionized treatment for EGFR-mutated lung cancer, however, acquired resistance is almost inevitable. The EGFR C797S mutation has recently been reported as a potential mechanism of resistance, however there are currently no approved targeted therapies for EGFR C797S mutation. Byoung Chul Cho, MD, PhD, Yonsei University College of Medicine in Seoul, Republic of Korea, reports on the results of a preclinical study exploring JIN-A02, a novel fourth-generation EGFR tyrosine kinase inhibitor (TKI) targeting the CT9TS mutation. Ba/F3 cell lines overexpressing human EGFR mutants or human EGFR wild-type and patient-derived cell lines harboring EGFR mutations were used. In vivo efficacy was also assessed. These preclinical models demonstrated JIN-A02 as a potential best-in-class fourth fourth-generation EGFR TKI with high potency and selectivity, showing robust activities against EGFR C797S mutations, as well as L718Q, for which there are currently no treatment alternatives.This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.